Keyphrases
Adjusted Odds Ratio
6%
AIDS/HIV
36%
Antiretroviral Therapy
27%
Bacteremia
5%
Cardiovascular Disease
5%
Cardiovascular Risk
6%
CD4 Count
16%
CD8+ T Cells
5%
Cell Culture
6%
Cell Culture Model
8%
Chronic Hepatitis C
15%
Cirrhosis
6%
Clinical Outcomes
6%
Combined Antiretroviral Therapy (cART)
10%
Community-acquired Pneumonia
12%
Comorbidity
20%
Confidence Interval
49%
Copenhagen
16%
COVID-19
52%
Denmark
92%
Diabetes
7%
Direct-acting Antivirals
7%
Epitope
5%
Europe
13%
EuroSIDA
5%
Genotype
13%
Genotype 1
15%
Genotype 2a
5%
Genotype 3
8%
Hazard Ratio
8%
Healthcare Workers
5%
Hepatitis B Virus
5%
Hepatitis C
11%
Hepatitis C Virus
72%
Hepatitis C Virus Genotypes
21%
Hepatitis C Virus Infection
13%
Hepatitis C Virus RNA
5%
Hepatocellular Carcinoma
5%
High Risk
7%
Highly Active Antiretroviral Therapy (HAART)
22%
HIV Infection
25%
HIV Patients
62%
HIV-positive
6%
Hospitalization
8%
Hospitalized Patients
6%
Human Immunodeficiency Virus Infection
7%
Human Immunodeficiency Virus Type 1 (HIV-1)
31%
Hypervariable Region
6%
Immigrants
9%
Incidence Rate
15%
Infected Individual
14%
Infected Patients
16%
Infectious Diseases
8%
Interferon-α (IFN-α)
5%
Interleukin-6
5%
Invasive Pneumococcal Disease
8%
JFH1
11%
Matched Cohort Study
7%
Meningitis
7%
Meta-analysis
6%
Migrants
10%
Mortality Rate
7%
Mycobacterium Tuberculosis (M. tb)
6%
Myocardial Infarction
6%
National Cohort Study
34%
Nationwide Registers
5%
Neutralizing Antibodies
12%
Non-associated
7%
NS5A
6%
Observational Cohort Study
5%
Odds Ratio
11%
Patients with COVID-19
7%
People Living with HIV (PLHIV)
49%
Placebo
6%
Polymorphism
5%
Population-based Cohort Study
6%
Prospective Cohort Study
9%
Protease Inhibitors
10%
Randomized Controlled Trial
12%
Randomized Trial
5%
Recombinant
14%
Refugees
12%
Register Study
7%
Relative Risk
6%
Retrospective Cohort Study
5%
Ribavirin
6%
Risk Factors
22%
Risk of Death
5%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
5%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
7%
Staphylococcus Aureus Bacteremia
14%
Sustained Virological Response
5%
Sweden
5%
Tuberculosis
10%
Tumor Necrosis Factor-α
5%
Vaccination
6%
Viral Load
7%
Viral Replication
5%
Virological Failure
5%
Virus
25%
Medicine and Dentistry
Antibiotics
5%
Antiretroviral Therapy
14%
Antivirus Agent
7%
Biological Marker
5%
Cardiovascular Disease
5%
Cell Count
5%
Chronic Hepatitis C
13%
Cohort Analysis
48%
Community-Acquired Pneumonia
10%
COVID-19
29%
Cross Sectional Study
6%
Diabetes
7%
Diagnosis
7%
Disease
19%
Hazard Ratio
9%
Hepatitis C
8%
Hepatitis C Virus
17%
Highly Active Antiretroviral Therapy
7%
Human Immunodeficiency Virus
100%
Human Immunodeficiency Virus Infection
16%
Immigrant
5%
Infection
43%
Liver Cirrhosis
5%
Logistic Regression Analysis
5%
Malignant Neoplasm
8%
Mortality Rate
6%
Odds Ratio
11%
Placebo
5%
Population
10%
Prevalence
18%
Prospective Cohort Study
7%
Randomized Controlled Trial
10%
Serotype
5%
Severe Acute Respiratory Syndrome Coronavirus 2
19%
Staphylococcal Bacteremia
7%
Symptom
13%
Systematic Review
7%